A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy

Summary

The objective of this clinical trial is to evaluate the efficacy and safety of BR1015 Combination therapy group in comparison with Fimasartan monotherapy group at Week 8 for essential hypertension patients who do not adequately responded by Fimasartan 30 mg

Timeline

Start

2022-11-09

Primary completion

2024-12-02

Completion

2024-12-02

Publications

• Youn JC, Lee SY, Yu CW, Sung KC, Shin J, Oh JH, Na JO, Kim DH, Cho EJ, Yoon HJ, Lee CJ, Lee HC, Lee HY, Sohn IS, Lee KS, Kim DI, Choi WG, Chung WJ, Lee EM, Choi SH, Choi S, Kang TS, Ihm SH. Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study. Drug Des Devel Ther. 2026 May 15;20:578736. doi: 10.2147/DDDT.S578736. eCollection 2026.

Drugs

Indications